Good morning, folks. And how are you today? We are in fine spirits, thanks to a sunny sky and a delightful breeze that are enveloping the Pharmalot campus. Of course, there is little time to enjoy the moment since there is so much to be done. No doubt, you can relate. So time to get cracking. Let’s grab that cup of stimulation — our choice today is maple bourbon — and attack the to-do list. Meanwhile, here are some items of interest. Hope you conquer the world today and keep us in mind if you hear anything interesting. …
Moderna (MRNA) cut its full-year sales forecast for its Covid-19 vaccine to between $15 billion and $18 billion from $20 billion estimated previously, as the vaccine maker struggles with the production of its two-dose inoculation, Reuters notes. The company is now expecting deliveries of between 700 million and 800 million doses this year, down from its prior expectations of between 800 million and 1 billion doses. The Covid-19 vaccine is now expected to generate between $15 billion and $18 billion in sales this year. That estimate was lowered because fewer doses are now set to be delivered this year and will instead be shipped in early 2022.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
